These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 25995443)

  • 21. [Evaluation of a new anti-cancer drug regimen for surface epithelial-stromal ovarian cancer].
    Fushiki H; Hidaka T; Hori S; Fujimura M; Yamakawa Y; Izumi R
    Gan To Kagaku Ryoho; 1998 Apr; 25(5):731-4. PubMed ID: 9571971
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Survivin expression as a prognostic factor in patients with epithelial ovarian cancer or primary peritoneal cancer treated with neoadjuvant chemotherapy.
    Gąsowska-Bodnar A; Bodnar L; Dąbek A; Cichowicz M; Jerzak M; Cierniak S; Kozłowski W; Baranowski W
    Int J Gynecol Cancer; 2014 May; 24(4):687-96. PubMed ID: 24662134
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differences of chemoresistance assay between invasive micropapillary/low-grade serous ovarian carcinoma and high-grade serous ovarian carcinoma.
    Santillan A; Kim YW; Zahurak ML; Gardner GJ; Giuntoli RL; Shih IM; Bristow RE
    Int J Gynecol Cancer; 2007; 17(3):601-6. PubMed ID: 17504374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Profiling of serum tumor markers in patients with epithelial ovarian carcinoma].
    Dong L; Li XP; Cui H; Wang JL; Wei LH; Zhao Y; Wang SJ; Wang Y; Sun XL; Liang XD; Li Y
    Zhonghua Fu Chan Ke Za Zhi; 2009 Feb; 44(2):121-5. PubMed ID: 19570423
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Chen X
    Arch Gynecol Obstet; 2017 Feb; 295(2):451-458. PubMed ID: 27913927
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Validated or not validated? That is the question.
    Bartlett JM; Pritchard KI; Spears M
    J Natl Cancer Inst; 2014 Jan; 106(1):djt360. PubMed ID: 24402423
    [No Abstract]   [Full Text] [Related]  

  • 27. Specific copy number alterations associated with docetaxel/carboplatin response in ovarian carcinomas.
    Osterberg L; Levan K; Partheen K; Delle U; Olsson B; Sundfeldt K; Horvath G
    Anticancer Res; 2010 Nov; 30(11):4451-8. PubMed ID: 21115892
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification of proteomic and metabolic signatures associated with chemoresistance of human epithelial ovarian cancer.
    Wu W; Wang Q; Yin F; Yang Z; Zhang W; Gabra H; Li L
    Int J Oncol; 2016 Oct; 49(4):1651-65. PubMed ID: 27511453
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer.
    Xu X; Deng F; Lv M; Ren B; Guo W; Chen X
    J Ovarian Res; 2016 Dec; 9(1):85. PubMed ID: 27912779
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma.
    Yen MJ; Hsu CY; Mao TL; Wu TC; Roden R; Wang TL; Shih IeM
    Clin Cancer Res; 2006 Feb; 12(3 Pt 1):827-31. PubMed ID: 16467095
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Spectrin αII and βII tetramers contribute to platinum anticancer drug resistance in ovarian serous adenocarcinoma.
    Maeda O; Shibata K; Hosono S; Fujiwara S; Kajiyama H; Ino K; Nawa A; Tamakoshi K; Kikkawa F
    Int J Cancer; 2012 Jan; 130(1):113-21. PubMed ID: 21328338
    [TBL] [Abstract][Full Text] [Related]  

  • 32. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
    Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
    Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic silencing of argininosuccinate synthetase confers resistance to platinum-induced cell death but collateral sensitivity to arginine auxotrophy in ovarian cancer.
    Nicholson LJ; Smith PR; Hiller L; Szlosarek PW; Kimberley C; Sehouli J; Koensgen D; Mustea A; Schmid P; Crook T
    Int J Cancer; 2009 Sep; 125(6):1454-63. PubMed ID: 19533750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant platinum-based chemotherapy in patients with epithelial ovarian cancer: prognostic factors and final outcome.
    Grivas A; Lianos E; Internos I; Papaxoinis G; Tselepatiotis E; Ziras N; Athanasiou AE
    J BUON; 2010; 15(4):647-51. PubMed ID: 21229624
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant Chemotherapy Followed by Maintenance Therapy With or Without Bevacizumab in Unresectable High-Grade Serous Ovarian Cancer: A Case-Control Study.
    Petrillo M; Paris I; Vizzielli G; Amadio G; Cosentino F; Salutari V; Scambia G; Fagotti A
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S952-8. PubMed ID: 26036187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy.
    Miller KR; Patel JN; Zhang Q; Norris EJ; Symanowski J; Michener C; Sehouli J; Braicu I; Destephanis DD; Sutker AP; Jones W; Livasy CA; Biscotti C; Ganapathi RN; Tait DL; Ganapathi MK
    Gynecol Oncol; 2018 Apr; 149(1):155-162. PubMed ID: 29402501
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Erosive osteoarthritis during treatment with bevacizumab and paclitaxel in a patient with recurrent papillary serous carcinoma of the ovary.
    Jaishuen A; Berrios-Rivera JP; Sirisabya N; Zheng HG; Li Y; Kavanagh JJ
    Int J Gynecol Cancer; 2008; 18(2):379-83. PubMed ID: 17624988
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum.
    Schmeler KM; Sun CC; Bodurka DC; Deavers MT; Malpica A; Coleman RL; Ramirez PT; Gershenson DM
    Gynecol Oncol; 2008 Mar; 108(3):510-4. PubMed ID: 18155273
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Advanced stage clear-cell epithelial ovarian cancer: the Hellenic Cooperative Oncology Group experience.
    Pectasides D; Fountzilas G; Aravantinos G; Kalofonos C; Efstathiou H; Farmakis D; Skarlos D; Pavlidis N; Economopoulos T; Dimopoulos MA
    Gynecol Oncol; 2006 Aug; 102(2):285-91. PubMed ID: 16516283
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ovarian cancer treatments on the horizon.
    Schmidt C
    J Natl Cancer Inst; 2011 Sep; 103(17):1284-5. PubMed ID: 21852261
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.